What is CMPS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.49B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CMPS?

P/E (TTM) is n/a and 52-week range is $4.88 to $15.87 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CMPS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CMPS?

The company profile lists net income (TTM) near -$469M, EPS (TTM) near -$3.47 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Compass Pathways PLC based, and what identifiers does Chartloom list?

The company context section lists headquarters in Altrincham, Cheshire, GB, 134.9M shares outstanding, ISIN US20451W1018 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Compass Pathways PLC

$CMPS

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Compass Pathways Plc is a biotechnology company, which provides mental health care services. The company is headquartered in Altrincham, Cheshire and currently employs 156 full-time employees. The company went IPO on 2020-09-18. The firm is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. The company commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. The company also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Employees

156

Website

compasspathways.com/

IPO

2020-09-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)